Lunai Bioworks Inc. (NASDAQ:LNAI) Sees Significant Growth in Short Interest

Lunai Bioworks Inc. (NASDAQ:LNAI) saw a large growth in short interest in the month of April. As of April 30th, there was short interest totaling 1,654,166 shares, a growth of 112.2% from the April 15th total of 779,601 shares. Currently, 6.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 3,972,748 shares, the short-interest ratio is presently 0.4 days.

Lunai Bioworks Stock Down 7.0%

Lunai Bioworks stock opened at $0.26 on Friday. Lunai Bioworks has a twelve month low of $0.15 and a twelve month high of $4.50. The company’s 50-day moving average price is $0.34 and its 200-day moving average price is $0.72. The company has a market cap of $6.22 million, a PE ratio of 5.14 and a beta of 0.34.

Lunai Bioworks (NASDAQ:LNAI) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.10) EPS for the quarter. The firm had revenue of $0.02 million for the quarter.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on LNAI. Wall Street Zen downgraded Lunai Bioworks from a “hold” rating to a “sell” rating in a research report on Saturday, February 21st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Lunai Bioworks in a research note on Friday, April 10th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Lunai Bioworks stock. Millennium Management LLC acquired a new position in Lunai Bioworks Inc. (NASDAQ:LNAI) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned 0.87% of Lunai Bioworks as of its most recent filing with the Securities & Exchange Commission. 71.41% of the stock is owned by institutional investors and hedge funds.

About Lunai Bioworks

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.